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Summary
The endoplasmic reticulum (ER) is an intracellular com-
partment dedicated to the synthesis and maturation of
secretory and membrane proteins, totalling about 30% of
the total eukaryotic cells proteome. The capacity to pro-
duce correctly folded polypeptides and to transport them
to their correct intra- or extracellular destinations relies on
proteostasis networks that regulate and balance the activ-
ity of protein folding, quality control, transport and degrad-
ation machineries. Nutrient and environmental changes,
pathogen infection aging and, more relevant for the topics
discussed in this review, mutations that impair attainment
of the correct 3D structure of nascent polypeptide chains
may compromise the activity of the proteostasis networks
with devastating consequences on cells, organs and organ-
isms’ homeostasis. Here we present a review of mechan-
isms regulating folding and quality control of proteins ex-
pressed in the ER, and we describe the protein degradation
and the ER stress pathways activated by the expression of
misfolded proteins in the ER lumen. Finally, we highlight
select examples of proteopathies (also known as conform-
ational disorders or protein misfolding diseases) caused by
protein misfolding in the ER and/or affecting cellular pro-
teostasis and therapeutic interventions that might alleviate
or cure the disease symptoms.
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Building-up the proteome
Folding the proteins in the endoplasmic reticulum (ER)
The N-glycan is the entry ticket for lectin-based chaperone
systems
The majority of the nascent polypeptides emerging in the
ER lumen are rapidly modified by covalent attachment
of pre-assembled oligosaccharides to asparagine residues
within a specific consensus motif (N-glycosylation) [1].
The transfer of the 14–units of oligosaccharide (three gluc-
oses, nine mannoses and two N-acetylglucosamines, fig. 1)
from a lipid donor in the ER membrane to nascent proteins
is mediated by the oligosaccharyltransferase complex
(OST) (fig. 2) [2]. N-glycosylation increases the solubility
of unstructured nascent polypeptide chains and supports
the recruitment of lectin (i.e. sugar-binding) molecular
chaperones and associated folding enzymes that catalyse
rate-limiting reactions during the folding process [3–5].
Binding of nascent proteins to malectin
Upon addition of the N-glycan, the outermost glucose
residue is immediately removed by the glucosidase I. The
resulting di-glucosylated N-glycan is a ligand for the ER
lectin malectin [6] that preferentially associates with newly
synthesised polypeptides that have entered off-pathways of
the folding programme and must be selected for rapid de-
struction (fig. 2) [7].
Binding of nascent proteins to calnexin (CNX) and
calreticulin (CRT)
Subsequent trimming of the second glucose residue by
glucosidase II generates a mono-glucosylated N-linked
Figure 1
Structure of the N-linked oligosaccharide. The oligosaccharide is
covalently bound to the side chain of asparagine residues in
asparagine(N)-any aminoacid(X)-serine(S) or threonine(T)
consensus motives.
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glycan that attracts CNX, a type I integral membrane lectin
chaperone, and its luminal paralogue CRT. Binding of
CNX and CRT as well as association with other molecular
chaperones such as BiP/GRP78 and GRP94 protect nascent
polypeptide chains from aggregation in the crowded ER
environment and initiate the folding programme (fig. 2) [8,
9].
CNX and CRT recruit factors that assist folding of nascent
polypeptides
CNX and CRT form functional complexes with ERp57 and
CypB [10]. These are members of the protein disulfide iso-
merase (PDI) and of the peptidyl-prolyl cis/trans isomerase
families that promote two rate-limiting steps during protein
folding, namely the formation of disulfide bonds (i.e., of
inter- and intra-molecular covalent bonds between the side
chains of cysteine residues) [11] and the cis/trans isomer-
isation of peptidyl-prolyl bonds (fig. 2).
Substrate association with CNX and CRT and the enzymat-
ic action of ERp57 and CypB are concluded by the removal
of the third glucose residue from the oligosaccharide dis-
played on newly synthesised proteins, which is operated
by glucosidase II (fig. 2) [12]. After release from the lectin
chaperones, the folding protein collapses into a three-di-
Figure 2
Folding cycle in the ER. The nascent polypeptide arising from the
ribosome is translocated into the ER lumen. The polypeptide is co-
translationally N-glycosylated by the OST. Hydrophobic patches
exposed by the not-yet native polypeptide are shielded by
molecular chaperones such as BiP to prevent aggregation. Upon
removal of the outermost glucose residue by glucosidase I, the
lectin malectin binds to the N-glycan. Removal of the second
glucose residue by glucosidase II, allows recruitment of CNX (or
CRT) and the associated folding enzymes (the oxidoreductase
ERp57 and the peptidyl-prolyl cis/trans isomerase CypB that
catalyse the rate-limiting steps of the folding programme leading to
the attainment of the correct configuration of disulfide and peptidyl-
prolyl bonds, respectively). The polypeptide is eventually released
from CNX, the third glucose residue is removed by glucosidase II,
and the polypeptide structure is inspected by the folding sensor
UGGT1. Native proteins are exported to the Golgi in COPII-coated
vesicles. Non-native polypeptides are re-glucosylated by UGGT1
and sent back to the CNX folding platform. Terminally misfolded
polypeptides are extensively de-mannosylated and dislocated
across the ER membrane to be degraded by cytosolic proteasomes
in processes collectively defined as ER-associated degradation
(ERAD).
mensional structure, which is carefully inspected by the ER
quality control system.
Checking the quality of proteins expressed in the ER
UGGT1: a quality control inspector in the ER lumen
The folding status of newly synthesised glycoproteins re-
leased by CNX and CRT is checked by the UDP-gluc-
ose:glycoprotein glucosyltransferase 1 (UGGT1) [13]. Nat-
ive proteins are ignored by the UGGT1 and can be exported
from the ER to their final intra- or extracellular destination
(fig. 2). Non-native polypeptides that display structural de-
fects such as surface-exposed hydrophobic patches are re-
cognised by the UGGT1 which then adds a terminal gluc-
ose residue to their N-glycans thereby re-generating a bind-
ing site for CNX/CRT (fig. 2) [8, 13]. Re-association of
non-native polypeptides with CNX/CRT exposes them
again to the action of folding enzymes that will re-arrange
disulfide and peptidyl-prolyl bonds, eventually promoting
the attainment of the native structure. Depending on the
nature of the polypeptide, only one or several cycles of
release/re-binding are necessary to obtain the native 3D
structure [14].
Getting rid of misfolded proteins
Extensive N-glycan processing generates the signal for
ER-associated degradation (ERAD)
In some cases, the newly synthesised proteins are folding-
defective because of mutations in the DNA or in the mRNA
that cause amino acids substitutions/deletions or premature
interruption of the polypeptide chain (fig. 2, fig. 3, step
1). For glycosylated proteins, the signal for destruction is
activated following prolonged retention in the ER lumen,
which is a symptom of problems in attaining the native
structure and consists in the extensive de-mannosylation of
the N-glycan by the ER-resident mannosidases ERManI,
EDEM1, EDEM2, EDEM3. These remove α1,2–bonded
mannose residues (fig. 1, dark green circles) from oligosac-
charides displayed on terminally misfolded polypeptides
[15]. De-mannosylated N-glycans recruit the ERAD lectins
OS-9 and XTP3–B that shuttle the misfolded protein to
large supramolecular complexes integrated in the ER mem-
brane, the dislocons (fig. 2, fig. 3, step 2) [16]. Dislocons
are built around membrane-embedded E3 ubiquitin ligases
and comprise, amongst other components, of PDIs [17, 18]
and PPIs [19] that unfold the polypeptide chain to be dis-
located across the ER membrane. The ER membrane con-
tains several distinct E3 ligase complexes with peculiar
substrate specificity that tag terminally misfolded poly-
peptides for degradation upon addition of long chains of
the small molecule ubiquitin. Extraction from the ER and
channelling of misfolded proteins to cytosolic proteasomes
is regulated by the ATP-driven chaperone VCP/p97 (fig. 3,
step 2) [16, 20, 21].
Quarantine for misfolded proteins
It has been observed that misfolded proteins may accumu-
late in a specialised sub compartment of the ER upon pro-
teasomal inhibition, the so-called ER quality control com-
partment (ERQC) [22]. The ERQC appears to function as
a deposit site for the toxic non-native protein species under
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conditions of proteasome dysfunction. Additionally, mis-
folded proteins that are retro-translocated from the ER can
be deposited in cytosolic aggresomes to prevent interferen-
ces with cellular functions [23].
Responding to ER stress
Conditions leading to ER stress
Accumulation of non-native polypeptides in the ER can
have detrimental consequences if not resolved. The cell can
encounter this situation following increased secretory de-
mands (e.g. insulin production in β cells of the pancreas,
antibody production of plasma cells), upon defective func-
tion of the chaperone machinery, environmental changes
such as redox, ions, nutrient imbalances, pathogen infec-
tion, differentiation, aging or, more relevant in this context,
the expression of mutated gene products [20].
Post-translational responses
In healthy cells, ERAD activity is tightly regulated. This
prevents the inappropriate destruction of non-native inter-
mediates of protein folding programmes that could occur
when un-physiologically high ERAD activity interferes
with ongoing folding programmes, or the intracellular ac-
cumulation of misfolded polypeptides as a consequence
of insufficient ERAD activity. A well-studied example of
pathologic consequences of de-regulated ERAD is the in-
appropriate destruction of the tumour suppressor KAI1 in
certain tumour cell types characterised by hyperactivity of
the E3 ubiquitin ligase gp78 that results in enhanced meta-
static potential [24].
Recent evidence reveals that adaptation of ERAD activity
is an early response following fluctuations of ER cargo
load, leading to a rise in immature polypeptides in the ER
lumen. This early response occurs at the post-translational
level, has been named ERAD tuning (fig. 3, step 3) and is
thoroughly described elsewhere [21, 25–27].
Transcriptional responses
When activation of post-translational programmes is in-
sufficient to relieve the stress situation and the ER load
reaches a certain threshold, transcriptional programmes are
triggered following signal transmission from the ER to the
nucleus (fig. 3, step 4). In mammals, the UPR is regulated
by three distinct pathways responding to the activation of
three ER-resident transmembrane “stress sensors”: ATF6
(activating transcription factor 6), IRE1 (inositol-requiring
enzyme 1) and PERK (protein kinase RNA-activated-like
ER kinase) (fig. 3, step 4). Under stress conditions, ATF6
and IRE1 activation results in transcriptional induction of
folding, degradation and lipid synthesis factors. PERK ac-
tivation attenuates cargo protein synthesis and may even-
tually trigger cell-death pathways [20, 28]. All in all, the
activation of the transcriptional UPR serves to re-establish
ER proteostasis or, if this fails, to eliminate the suffering
cell from the organism. While cells can adapt to mild forms
of ER stress [29], severe chronic stress may lead to cell
death and thereby to destruction of the affected tissue [20].
Cells in aged individuals show a decreased ability to ac-
tivate the pro-survival arms of the UPR, which may en-
hance the risk and worsen the outcome of diseases related
to impaired ER proteostasis [30–32]. Interestingly, it has
recently been shown in C. elegans that the aging process
can be slowed down by ectopic expression of XBP1s in
neurons [33]. Crucial for the enhanced lifespan is the se-
cretion of neurotransmitters from XBP1s-expressing neur-
ons to other tissues. Hence, ER stress signalling between
tissues appears to be important for the maintenance of ER
proteostasis in C. elegans, which might also be the case in
higher organisms.
Bad news and good news
Figure 3
Responses to misfolded proteins in the ER. Misfolded protein
species can arise due to the error-proneness of the folding process
or due to mutations (red asterisk in step1). They are selected for
ERAD (step 2). At steady state, post-translational mechanisms,
collectively termed ERAD tuning, are in place to keep ERAD activity
under control (step 3). Accumulation of misfolded polypeptides in
the ER lumen may trigger the UPR (step 4). IRE1 forms active
clusters that remove a short intron from the XBP1 mRNA thus
resulting in expression of the active transcription factor XBP1s.
ATF6 is transported to the Golgi, where it is cleaved to release the
active transcription factor ATF6f. XBP1s and ATF6f are eventually
dislocated into the nucleus, where they activate expression of ER
stress-induced genes. PERK forms clusters that phosphorylate the
elF2α elongation factor thereby attenuating cargo protein synthesis.
On the contrary, the translation of the transcription factor ATF4 is
specifically enhanced under these conditions and induces the
expression of UPR genes.
Figure 4
Schematic of the proteostasis network. The main components that
regulate and maintain protein homeostasis (proteostasis) are
illustrated as gears of a machine.
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The bad news: conformational diseases
As with every biological process, protein biogenesis is
prone to errors. Attempts to determine the average effi-
ciency of protein folding programmes gave contradictory
results with values ranging from 70% [34] to substantially
more than that [35]. As for individual proteins, one could
report the examples of α1–antitrypsin (A1AT), whose fold-
ing efficiency approaches the 90% [36], and of the cystic
fibrosis trans-membrane regulator (CFTR), whose matur-
ation is much less efficient (20–40 % [37]). These values
may dramatically drop upon errors occurring during tran-
scription, translation, post-translational modifications thus
determining the onset of so-called conformational diseases
(proteopathies, protein misfolding diseases), which result
from degradation (loss-of-function) or intra-/extra-cellular
accumulation (gain-of-toxic-function) of mutant polypep-
tides [38, 39]. The cases of hereditary lung emphysema
and of cystic fibrosis (CF) are paradigmatic examples of
this type of disease. In hereditary lung emphysema, the re-
placement of a glutamic acid at position 342 with a lysine
in the A1AT sequence is sufficient to cause a 90% reduc-
tion in circulating A1AT. This results in defective protec-
tion of lung tissues from destructive proteases released by
neutrophils during inflammations [40]. For CF, a deletion
of a single phenylalanine at position 508 virtually abolishes
CFTR folding thereby causing its clearance from cells [41]
(and see below).
The terms proteopathies, conformational disorders, protein
misfolding diseases refer to a group of disorders in which
certain proteins fail to attain their normal conformation,
resulting in degradation (loss-of-function) or accumulation
(gain-of-toxic-function) of the aberrant products. Here we
highlight a few selected examples:
Loss-of-function
Cystic fibrosis
CF is an inherited disorder characterised by the accumula-
tion of mucus at the epithelial surfaces of several organs,
such as the lungs, pancreas and gut [42–44]. This hyper-
production of mucus predisposes the tissues for inflam-
mation and chronic infection that may lead to respiratory
failure, the most common cause of death in CF patients.
Although treatments have been improved, the disease may
progress to levels of gravity where lung or even multi-or-
gan (liver and pancreas are also affected) transplantation
represents the last solution to prolong life expectancy [45].
CF is caused by mutations that affect the folding of the
CFTR, a large multi-domain protein that, even in its wild
type form, has low folding efficiency [37]. CFTR biogen-
esis starts in the ER, where the nascent polypeptide asso-
ciates with CNX. Only about 20–40% of the newly syn-
thesised CFTR properly reaches the cell surface. Most of
it is rapidly degraded from the ER. Mutations in the CFTR
gene may fully prevent folding or may delay it to such an
extent that the protein is selected for disposal before it ac-
tually attains the native, transport-competent conformation
thus causing this loss-of-function disease [37, 41].
Metabolic storage disorders
Metabolic storage disorders are caused by mutations that
lead to insufficient activity of select enzymes. In particular,
metabolic storage disorders include a subgroup of diseases
in which the lysosomal activity is impaired, the so-called
“lysosomal storage disorders” [46]. The deficiency of a
single enzyme may compromise the overall lysosomal de-
gradative capacity thereby resulting in the toxic intracel-
lular accumulation of lysosomal substrates [47]. The most
prominent lysosomal storage disorders are Gaucher’s and
Fabry’s diseases, which are determined by deficient activ-
ity of the housekeeping enzymes beta-glucocerebrosidase
(GBA) and alpha-galactosidase A (α-Gal A), respectively
[48].
Gaucher’s disease is characterised by glucosylceramide
(GC)/glucosylsphingosine (GS) accumulation in visceral
organs (type 1) or in the central nervous system (type 2 and
3) [49]. More than 300 mutations have been identified in
the GBA gene, leading to premature termination or dele-
tions [50]. Mutant GBA variants are recognised as misfol-
ded proteins inside the ER and thus targeted for ERAD, res-
ulting in glycosphingolipid catabolism interruption.
Fabry’s disease is characterised by progressive accumula-
tion of glycosphingolipids in the lysosomes of vascular en-
dothelial cells. The α-Gal A sequence has high content of
Alu sequences, resulting in propensity for gene deletions
and duplications [47]. Recently, one novel disease-causing
mutation has been described: this mutation is close to the
N-glycosylation site, causing premature termination and
leading to degradation of the aberrant product [51].
Haemophilia A
Haemophilia A (HA), also known as “royal disease”, is a
genetic disorder characterised by increased bleeding. HA
is caused by deficient activity or absence of clotting factor
VIII (FVIII) [52]. FVIII is a large glycoprotein that folds
in the CNX/CRT cycle [53]. Based on the severity of FVIII
deficiency, HA has been divided in three clinical categor-
ies: mild (5–40% FVIII activity), moderate (1–5%) and
severe deficiency (<1%). Classic HA is determined by dif-
ferent types of mutations in the FVIII gene, such as point
mutations, deletions, insertions and intron inversions [52].
Mutations that cause conformational changes in the FVIII
protein or lead to truncated versions of FVIII correlate with
a severe degree of the pathology.
Gain-of-toxic-function
Alzheimer’s and Parkinson’s diseases
Alzheimer’s disease (AD) and Parkinson’s disease (PD)
represent the most common neurodegenerative disorders
characterised by progressive neuronal loss affecting
defined areas of the brain [54]. Both pathologies are as-
sociated with the deposition and aggregation of misfolded
proteins that cause neurodegeneration by a gain-of-toxic
function mechanism [55]. Several mechanisms have been
proposed to explain the toxicity annexed to the accumu-
lation of protein aggregates, including impairment of pro-
teasomal/lysosomal degradation and induction of ER
stress.
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In AD, the amyloid precursor protein APP is sequentially
cleaved by β- and γ-secretases determining the production
of the beta-amyloid peptide (Aβ). APP or secretases muta-
tions may cause an increase in Aβ production leading to
its deposition and extracellular amyloid plaques formation
[56]. Intracellular neurofibrillary tangles have also been as-
sociated to AD. These filamentous aggregates are com-
posed of tau, a protein that is involved both in the assembly
and in the stabilisation of microtubules [57]. Tau protein is
subjected to several post-translational modifications such
as phosphorylation. It has been reported that hyper-phos-
phorylation of tau causes its instability and drives its sedi-
mentation into the intracellular toxic tangles [54].
The typical hallmark of PD is the presence of the so-called
Lewy bodies within the cytoplasm of dopaminergic neur-
ons. The first gene associated to PD is α-synuclein, which
encodes for a protein that is widely expressed in the brain
and defined as intrinsically disordered [58]. It has been
shown that altered expression levels, mutations and hyper-
phosphorylation events of α-synuclein correlate with the
toxic effects observed in the course of the pathology.
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disorder affecting motor neurons, which is characterised by
gradual paralysis and muscle atrophy. ALS disease is asso-
ciated with protein aggregates commonly found in spinal
motor neurons. These inclusions are ubiquitin-positive and
contain several proteins involved in mitochondrial and ER
homeostasis [59, 60]. The most common aggregated pro-
tein is superoxide dismutase 1 (SOD1), whose mutations
found in ALS cause misfolding and instability.
The good news: Approaches to treat conformational
diseases
Test tube and cell culture experiments contribute to a thor-
ough understanding of processes regulating ER proteostas-
is (fig. 4), which has helped to develop drugs for the treat-
ment of proteopathies. Although some of these drugs have
made it to clinical trials and beyond, more in vitro and in
vivo studies are necessary to elucidate their precise mech-
anism of action and to find novel druggable targets. There
are numerous ways to approach conformational diseases
including (1) enzyme replacement therapy (ERT) for loss-
of-function diseases, (2) enhancement of mutant protein
folding capacity with chemical or pharmacological chaper-
ones and (3) activation of the UPR by small molecules [48,
61].
ERT by administration of recombinant proteins
An obvious way to counteract loss-of-function diseases is
the replacement of the mutated protein by a functional, re-
combinant one. A drawback of this therapeutic approach is
the dependence of the patients on repeated doses of the re-
combinant enzymes. Costs are another critical issue, espe-
cially for patients with rare diseases because therapy costs
inversely correlates with the number of patients. The diffi-
culty of this approach lies in the protocol of administration
of the replacing protein. In the case of soluble proteins such
as insulin (ERT for diabetes) or β-glucosidase (ERT for
Gaucher’s disease), subcutaneous or intravenous adminis-
tration works [62, 63]. Exogenous insulin will be trans-
ported via the bloodstream to its target tissues, exogenous
β-glucosidase (or other lysosomal enzymes) will be taken
up by cells and delivered via the endocytic pathway to the
lysosomes where they operate. Thus, ERT treatments are
successfully used for diabetes, Gaucher’s and Fabry’s dis-
ease, mucopolysaccaharidose I, II and VI or HA [63–66].
However, ERT can generally not be used to cure or prevent
neuropathic diseases as the blood brain barrier does not al-
low efficient transport of the replacing enzyme [67], or to
compensate the defective production of membrane-inser-
ted enzymes such as the CFTR because correct insertion
in the membranes, especially for polytopic membrane pro-
teins, can only occur during the synthesis of the polypep-
tide.
ERT by gene therapy
An alternative, more broadly applicable approach to treat
loss-of-function disease is to deliver the missing protein in
patients by gene therapy. To this end, modified viral vectors
containing the gene-of-interest are injected into patients.
The use of viral vectors is problematic as it bears the risk of
triggering potentially lethal immune reactions (adenovirus-
based vectors) or cancer (retrovirus-based vectors) as illus-
trated by tragic examples in clinical trials [68]. However,
improvement of the safety of viral vectors has raised new
hope for the use of gene therapy. A successful example is
the expression of clotting factor IX in haemophilia B pa-
tients with the help of liver-targeted adeno-associated virus
(AAV) vectors in the absence of side effects [69, 70]. The
first gene therapy protocol that was approved for clinical
use in Europe in 2012 is a treatment for familial lipoprotein
lipase deficiency based on AAV vector-mediated delivery
of lipoprotein lipase [71]. An alternative to the use of vir-
al vectors is gene delivery by liposomes. This approach is
currently tested in clinical trial studies for CF [72].
Chemical chaperones
Certain chemical compounds that non-covalently interact
with mutant proteins are able to stabilise folding interme-
diates and have the potential to enhance folding capacity.
These are defined as chemical chaperones. Chemical chap-
erones such as 4–phenylbutyric acid sodium salt (PBA)
and tauroursodeoxycholic acid (TUDCA) reduce ER stress
in mouse models of type 2 diabetes [73] and, as it is the
case for PBA, are approved by the US Food and Drug
Administration for clinical use [74, 75]. Another chemic-
al chaperone, betaine, prevents aggregation and improves
ER-to-Golgi transport of a trafficking-defective mutant of
coagulation factor FVIII, thereby restoring its function in
a mouse model of HA [66]. Despite these successful ex-
amples of chemical chaperone therapy, the mechanisms of
action are largely unknown and unspecific. Furthermore,
high concentrations have to be used that may have toxic
side effects [76]. Thus, the development of more specific-
ally acting drugs is of great clinical interest.
Pharmacological chaperones
Pharmacological chaperones are molecules that are de-
signed to enhance folding or to stabilise specific proteins-
of-interests. There are various examples of pharmacolo-
gical chaperones that are performing well in ameliorating
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conformational diseases. An example is the galactose de-
rivative 1–deoxygalactonojirimycin (DGJ), which is cur-
rently in phase III clinical trials for treatment of Fabry’s
disease [48]. DGJ stabilises mutant α-Gal A by binding to
the active site, thereby facilitating its folding in the ER,
preventing its selection for degradation and resulting in
a substantial increase of active α-Gal A that eventually
traffics to the lysosome. As the interaction is pH-depend-
ent, DGJ dissociates from the α-Gal A active site in the
acidic environment of the lysosome leaving a fully active
enzyme. Similar compounds that stabilise the disease-caus-
ing mutated proteins in Gaucher’s disease and GM1–gangli-
osidosis (i.e. GBA or β-galactosidase respectively) are in
phase I clinical trials [48].
Similar trials have been performed in the context of CF
treatments. The pharmacological chaperone Lumacaftor
(VX-809) promotes folding and cell surface transport of
CFTR ΔF508 in vitro. However, it does not prevent the
manifestation of CF in vivo, probably due to the com-
promised cell surface stability of mutant CFTR [77, 78].
A promising strategy to solve this issue seems to combine
Lumacaftor with other stabilising drugs such as Ivacaftor
(VX-770), which successfully treats patients with the rare
CFTR Gly551Asp mutation by enhancing the opening time
of CFTR channels [46, 77, 79].
Another pharmacological chaperone that has entered phase
II and III clinical trials is Tafamidis (Vyndaqel®, Pfizer).
Tafamidis stabilises mutant transthyretin (Val30Met) tetra-
mers thereby preventing formation of toxic fibrils in pa-
tients with transthyretin familial amyloid polyneuropathy
[46, 80].
UPR modulation by small molecules
As UPR signalling help cells to re-establish proteostasis
by enhancing folding and ERAD capacities, UPR modula-
tion might be instrumental to treat certain loss-of-function
conformational diseases such as lysosomal storage disease
and CF, and gain-of-toxic function diseases such as AD,
PD and prion disease. As an example, small molecule UPR
activators or inhibitors are under scrutiny in an attempt to
improve ER proteostasis by either global UPR modulation
or by manipulation of specific arms of the UPR signalling
pathway. Possible risks of pharmacologic UPR induction
are the induction of cell death [20] or cancer [81].
Modulators of ATF6 or IRE1 activity
The ATF6 and IRE1 arms of the UPR are druggable targets
in conformational diseases. Even though only few small
molecule activators of ATF6 or IRE1 have been reported
so far and their potential use in vivo has yet to be estab-
lished [61, 82, 83], the aggregation of rhodopsin mutants
associated with autosomal dominant retinitis pigmentosa
was reduced following over-expression of either ATF6 or
IRE1 in cultured primary cells, resulting in improved sur-
vival of photoreceptor cells [76, 84, 85]. Furthermore, ag-
gregation of the disease causing PIZ variant of A1AT was
reduced following over-expression of the cytosolic domain
of ATF6, which is an active inducer of chaperone transcrip-
tion, due to enhanced ERAD activity [86].
Modulators of PERK or eIF2α activity
PERK induction attenuates cargo protein load by phos-
phorylation of eIF2α thereby reducing the ratio of folding
intermediates to chaperones operating in the ER. This
might improve the chances of mutated proteins to be prop-
erly folded [61]. Thus, prolongation of eIF2α phosphoryla-
tion with small molecules seems to be a promising strategy
to ameliorate conformational diseases. As prolonged eIF2α
phosphorylation might induce cell death, drugs are fa-
voured that specifically act under conditions of ER stress,
but not constitutively. One such small molecule is
Guanabenz, already approved as a drug for the treatment
of hypertension, which specifically inhibits eIF2α de-phos-
phorylation under conditions of UPR induction. The bene-
ficial effect of Guanabenz on the survival of pancreatic β
cell lines expressing mutant insulin, suggests its potential
use for treatment of diabetes or other diseases caused by in-
efficient folding of mutant proteins [87, 88].
In contrast, translational inhibition mediated by PERK can
worsen neurological pathologies. Patients with AD or prion
disease show hyper-phosphorylation of eIF2α, which has
been associated with decreased memory and synaptic plas-
ticity. A recent report by Ma and colleagues suggests that
deletion of PERK rescues this phenotype in AD mouse
models and that targeting PERK might improve the symp-
toms of AD patients [88]. On the same lines, Moreno et al.
demonstrate the beneficial effects of the specific PERK in-
hibitor GSK2606414 on prion-infected mice [89].
Conclusions and future perspectives
Production and maintenance of a functional proteome is
crucial for cells, tissues and organisms viability. Highly ef-
ficient folding, quality control and transport machineries
located in specific intracellular compartments such as the
ER convert the genetic information stored into the cell nuc-
lei into functional proteins and protein complexes that ful-
fil the wide array of functions required for life. Paradox-
ically, mutations that do not affect the function of a given
polypeptide may result in debilitating and life threatening
diseases if they introduce small structural defects. In fact,
the quality control devices that prevent exit of aberrant
polypeptides from the biosynthetic compartment and insure
their clearance from cells are alerted by non native fea-
tures such as exposure at the polypeptide surface of hydro-
phobic patches, unpaired cysteine residues or otherwise un-
structured determinants, independent of the capacity of the
mutant polypeptide to fulfil its biological activity. Cystic
fibrosis, where active CFTR molecules are degraded from
the ER because point mutations slightly alter the native 3D
structure, is a paradigmatic example thereof. This “qual-
ity control paradox” highlights the importance of basic re-
search in cell biology aiming at understanding the molecu-
lar basis of retention- and degradation-based mechanisms
operating in our cells. Characterisation of these processes
at the molecular level is required to develop therapeutic
interventions that promote selective export of functional
mutant proteins inappropriately segregated for architectural
biases or to sustain “unfolded protein responses” that must
intervene when misfolded polypeptides start to accumulate
in or outside cells. This becomes even more important for
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aging-related diseases such as many neurodegenerative dis-
orders, which result from gradual impairment of the pro-
teostasis network (fig. 4), as the increased life expectancy
is a fact in our society, and the number of patients will in-
eluctably raise.
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Figures (large format)
Figure 1
Structure of the N-linked oligosaccharide. The oligosaccharide is covalently bound to the side chain of asparagine residues in asparagine(N)-
any aminoacid(X)-serine(S) or threonine(T) consensus motives.
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Figure 2
Folding cycle in the ER. The nascent polypeptide arising from the ribosome is translocated into the ER lumen. The polypeptide is co-
translationally N-glycosylated by the OST. Hydrophobic patches exposed by the not-yet native polypeptide are shielded by molecular
chaperones such as BiP to prevent aggregation. Upon removal of the outermost glucose residue by glucosidase I, the lectin malectin binds to
the N-glycan. Removal of the second glucose residue by glucosidase II, allows recruitment of CNX (or CRT) and the associated folding
enzymes (the oxidoreductase ERp57 and the peptidyl-prolyl cis/trans isomerase CypB that catalyse the rate-limiting steps of the folding
programme leading to the attainment of the correct configuration of disulfide and peptidyl-prolyl bonds, respectively). The polypeptide is
eventually released from CNX, the third glucose residue is removed by glucosidase II, and the polypeptide structure is inspected by the folding
sensor UGGT1. Native proteins are exported to the Golgi in COPII-coated vesicles. Non-native polypeptides are re-glucosylated by UGGT1 and
sent back to the CNX folding platform. Terminally misfolded polypeptides are extensively de-mannosylated and dislocated across the ER
membrane to be degraded by cytosolic proteasomes in processes collectively defined as ER-associated degradation (ERAD).
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Figure 3
Responses to misfolded proteins in the ER. Misfolded protein species can arise due to the error-proneness of the folding process or due to
mutations (red asterisk in step1). They are selected for ERAD (step 2). At steady state, post-translational mechanisms, collectively termed
ERAD tuning, are in place to keep ERAD activity under control (step 3). Accumulation of misfolded polypeptides in the ER lumen may trigger the
UPR (step 4). IRE1 forms active clusters that remove a short intron from the XBP1 mRNA thus resulting in expression of the active transcription
factor XBP1s. ATF6 is transported to the Golgi, where it is cleaved to release the active transcription factor ATF6f. XBP1s and ATF6f are
eventually dislocated into the nucleus, where they activate expression of ER stress-induced genes. PERK forms clusters that phosphorylate the
elF2α elongation factor thereby attenuating cargo protein synthesis. On the contrary, the translation of the transcription factor ATF4 is
specifically enhanced under these conditions and induces the expression of UPR genes.
Review article: Medical intelligence Swiss Med Wkly. 2014;144:w14001
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 12 of 13
Figure 4
Schematic of the proteostasis network. The main components that regulate and maintain protein homeostasis (proteostasis) are illustrated as
gears of a machine.
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